SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain and as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is trending amid mixed sentiments, with some traders expressing frustration over recent price action and perceived manipulation, while others point to upcoming developments like the Goliath testnet and the multichain wallet launch as potential catalysts. The community is actively debating the coin's utility and future prospects, with discussions ranging from short-term trading strategies to long-term investment theses. There's also discussion around the correlation between Onyxcoin and the broader crypto market.

Mannatech, Inc. engages in the development of nutritional supplements, topical and skin care products and weight-management products that target optimal health and wellness. Its product category includes integrative health, targeted health, wealth and fitness, skin care, essentials, and home. The company was founded by Marlin Ray Robbins and Samuel L. Caster in November 1993 and is headquartered in Flower Mound, TX.

Mannatech Inc

MTEX is trending due to its low float and recent price action, sparking community discussion about a potential squeeze. Traders are closely watching key breakout levels, anticipating a significant move if volume increases. The stock's history of rapid gains and recent after-hours activity is fueling speculation and interest.

1 dog can change your life

The 1DOG crypto is trending, with community members highlighting positive chart patterns and increased volume, especially among Phantom Wallet users. There's a strong sense of "meme energy" around the token, with many anticipating a potential moonshot similar to DOGE or SHIB. Community buzz emphasizes joining the "pack" and not missing out.

StarHeroes is the first-ever multiplayer space shooter game designed for esports. The game has been developed since 2021 by GameSwift's subsdiary STAR studio, and offers fast-paced multiplayer galactic battles. StarHeroes provides both web3 and web2 modes, making its innovative gameplay accessible to a wide range of players. The web3 mode is based on a single token $STAR as well as NFTs. The $STAR token has the following utilities:  -Purchase of in-game spaceships -Purchase of in-game fuel to increase the number of games that allow a player to earn $STAR  -Leveling-up of the player’s NFT Hero -Purchase of missions for the player’s NFT Hero -Purchase of a feature that reduces mission time for the player’s  NFT Hero -Staking -Airdrop based on the in-game leaderboard -Share in Real Yield from the StarHeroes game -Governance   StarHeroes is currently in closed beta available to a selected number of players. The Early Access version will be launched in Q1 2024, while the full version is scheduled for Q2 2024.

Starbase

Starbase (STAR) is trending amid community excitement, with some linking it to Elon Musk's Starbase and increased chatter on Twitch. Discussions revolve around its utility beyond trading and how to acquire the coin, while some users are pointing out it could be related to other projects.

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

ICP is trending as the community debates its future and potential amid discussions around its technology and recent price movements. Some investors express frustration and call it a "scam," while others see its current price as a buying opportunity, citing its underlying technology and AI capabilities. Community members are also closely watching for increased adoption and institutional interest as potential catalysts.

Numeraire

Numeraire is trending as traders discuss its potential, citing its limited supply and connection to AI. The community is speculating on possible price movements, noting the coin's behavior relative to broader market trends like Bitcoin. Some are pointing to its unique use case in crowdsourced machine learning for hedge funds, while others highlight previous price surges.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic ($LUNC) is trending amidst community discussions about its price action and potential for recovery, with some holders expressing frustration over recent dips. Despite concerns, some community members remain optimistic, discussing potential future pumps and the impact of projects aimed at reviving the ecosystem. The conversation also includes broader market factors and the possible influence of external events.

Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. It utilizes Artificial Intelligence to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. It offers NOCISCAN Suite, a revolutionary software suite that works with existing high field Magnetic Resonance systems and Magnetic Resonance Spectroscopy pulse sequence packages using an optimized protocol to conduct MRS exams of lumbar discs. The company was founded by James C. Peacock, David S. Bradford, and Jeffrey Lotz in 2008 and is headquartered in Broomfield, CO.

Aclarion Inc

Aclarion ($ACON) is trending due to community speculation around its low float and potential for significant upside, with some eyeing it as a "monster potential" play. Discussions also involve potential catalysts like news from a presentation and speculation about buyouts, amid a broader market context of shifting investment sentiment related to China tariffs. Community members are actively discussing price targets and anticipating potential moves, both bullish and bearish.

Assemble’s AI agent, News3(NS3), was developed with the goal of revolutionizing Web 3.0 journalism. NS3 delivers crypto and global economic trends quickly and clearly, and leverages advanced AI reasoning capabilities to analyze these trends, enabling market participants to make data-driven decisions. In particular, NS3 utilizes OpenAI’s latest reasoning model as its core engine to analyze crypto and economic trends, providing a range of insights including market psychology, past case analysis, future predictions, ripple effects, and investment strategies in 12 languages.

Assemble Protocol

Assemble Protocol ($ASM) is trending as traders discuss its potential within the AI crypto sector, with some anticipating a breakout and highlighting its low market cap. Community members are actively debating potential catalysts, including a possible Binance listing and new developments, while others express frustration with price volatility. Some users cite whale activity and technical indicators as reasons for optimism, while others remain skeptical.

Coupang, Inc. engages in the provision of retail, restaurant delivery, video streaming, and fintech services to customers around the world under brands that include Coupang, Coupang Eats, Coupang Play, and Farfetch. It operates through the Product Commerce and Developing Offerings segments. The Product Commerce segment consists of the company's core retail and marketplace offerings and Rocket Fresh, its fresh grocery category offering. It also includes advertising products associated with these offerings. The Developing Offerings segment covers the company's more nascent offerings and services including: Coupang Eats, a restaurant ordering and delivery service in Korea, Coupang Play, an online content streaming service in Korea, fintech services, retail operations in Taiwan, as well as advertising products associated with these offerings. It also includes Farfetch, a global luxury fashion marketplace. The company was founded by Bom Kim in 2010 and is headquartered in Seattle, WA.

Coupang Inc - Ordinary Shares - Class A

Coupang Inc 

Coupang is trending as investors discuss its potential expansion into the U.S. e-commerce market, building on its success in South Korea; however, some analysts caution about e-commerce competition and its current valuation. The community is actively evaluating options strategies and discussing the company's growth prospects in AI and international markets.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts Believe Bright Minds Biosciences Inc. (DRUG) Could Rally 81.29%: Here's is How to Trade

The consensus price target hints at an 81.3% upside potential for Bright Minds Biosciences Inc. (DRUG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Bright Minds Biosciences Inc. (DRUG) Have the Potential to Rally 114.07% as Wall Street Analysts Expect?

The consensus price target hints at an 114.1% upside potential for Bright Minds Biosciences Inc. (DRUG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

What's Going On With Bright Minds Biosciences Stock Friday?

Bright Minds Biosciences shares are moving higher on Friday. The company announced a $35 million non-brokered private placement.
read more...

Shares of nanocap Bright Minds Biosciences, Inc. (<a class="mention" data-mention="$DRUG" data-symbol-id="DRUG" href="https://stocktwits.com/symbol/DRUG" target="_blank">$DRUG</a>) surged 47% in pre-market trading on Friday, making it one of the top five trending tickers on Stocktwits.The spike followed the company’s announcement of a non-brokered private placement of common shares priced at $21.70 per share, Thursday’s closing price, with aggregate gross proceeds expected to reach up to $35 million.Bright Minds intends to allocate these funds toward research and development for its drug development programs, as well as general working capital.Just two days prior, Bright Minds announced promising data from preclinical testing of BMB-201, a non-opioid alternative for neuropathic pain relief, conducted in partnership with the National Institutes of Health’s pain screening program.In nerve ligation pain models, BMB-201 demonstrated efficacy comparable to morphine, exhibiting superior reductions in mechanical allodynia and pain-related behaviors.The company stated that BMB-201 might provide better pain relief than traditional opioid treatments while mitigating the risks of dependency and adverse side effects.With these encouraging preclinical results, Bright Minds plans to advance BMB-201 into clinical trials to further assess its safety and efficacy in human subjects.Additionally, Firefly Neuroscience ($AIFF) had also announced a collaboration with Bright Minds to analyze data from its first-in-human Phase 1 study of its lead compound, BMB-101.Earlier this week, DRUG became an <a href="https://stocktwits.com/news-articles/markets/equity/drug-stock-falls-pre-market-after-1500-percent-surge/cJczTIWR4H">unlikely top gainer</a> across U.S. exchanges, soaring over 1,440% without any apparent catalyst. This prompted the company to issue a statement noting it was “unaware of any material changes in the company’s operations that would account for the recent increase in market activity.”On Stocktwits, the retail following for DRUG has surged 125% over the past week, while message volume has skyrocketed by over 290 times in the past month.Read next: <a href="https://stocktwits.com/news-articles/markets/equity/axp-stock-falls-premarket-after-q3-earnings/cJ22K06RIm">AmEx Stock Dips Pre-Market On Q3 Revenue Miss, But Retail Focuses On Bright Spots</a>

Bright Minds intends to allocate these funds toward research and development for its drug development programs, as well as general working capital.

Bright Minds Biosciences Stock Back In Retail’s Spotlight With $35M Funding Round Via Private Placement

Just two days prior, Bright Minds announced promising data from preclinical testing of BMB-201, a non-opioid alternative for neuropathic pain relief

Equity

Just two days prior, Bright Minds announced promising data from preclinical testing of BMB-201, a non-opioid alternative for neuropathic pain relief


Shares of Bright Minds Biosciences, Inc. ($DRUG) dropped by as much as 34% in pre-market trading on Wednesday after an enormous 1,445% surge in the previous session.Despite the apparent profit-booking, retail interest remains high.The Vancouver-incorporated biotech company issued a press release late Tuesday stating it was “unaware of any material changes in the company’s operations that would account for the recent increase in market activity.”That was reportedly in response to a request from the Canadian Investment Regulatory Organization, which oversees trading on the company’s home exchange.On Stocktwits, DRUG was the top trending ticker early Wednesday, with message volume spiking nearly 2,500% in the previous session. Retail interest surged, with the stock gaining 71% more followers.<stembedurl>https://stocktwits.com/TheRealShortSqueezy/message/588993273</stembedurl><stembedurl>https://stocktwits.com/etrade/message/588956007</stembedurl>Pre-market trading volume as of 7:15 a.m. ET, Wednesday, was at about 600,000 shares, far exceeding the daily average of just 24,000.Bright Minds focuses on developing drugs targeting serotonin-mediated diseases, and recently started a Phase 2 trial for a treatment aimed at drug-resistant epilepsy.The company, which has yet to generate any revenue, in August reported a net loss of $1.8 million for the nine months ending June 30, 2024 — down significantly from a $5.8 million loss during the same period in 2023.With $6.2 million in cash and working capital of $6.1 million, it said it has sufficient funds to operate through 2026.As of Tuesday’s close, Bright Minds’ stock has gained 1,991% year-to-date.The sudden rise sent its market cap soaring from $4 million to nearly $172 million before the pre-market drop.

Bright Minds focuses on developing drugs targeting serotonin-mediated diseases.

Bright Minds Biosciences Stock Falls Pre-Market After Whopping 1,445% Gain, But Retail’s Still Hooked

The biotech company issued a press release late Tuesday stating it was “unaware of any material changes in the company’s operations that would account for the recent increase in market activity.” 

DRUG Stock Sees Profit-Booking Pre-Market After Massive 1,445% Gain, But Retail’s Still Hooked

Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy

Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy Bright Minds Biosciences Initiates the...

Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company was founded by Ian B. McDonald and Alan P. Kozikowski on May 31, 2019 and is headquartered in New York, NY.

Bright Minds Biosciences Inc

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

Current Price	$63.29
Prev Close	$61.41
Open	$61.70
Dividend Yield	0.00%
50-Day Moving Average	$46.12
Beta	1.08
Avg. Volume	104,646.00
PE Ratio	-66.87

52-Week High	$79.02
52-Week Low	$1.11
Market Capitalization	$616.36M
EPS (Annual)	-$0.4777
Price to Book	11.80
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

DRUG
Bright Minds Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DRUG News

DRUGBright Minds Biosciences Inc